Gilead Sciences, Inc stock page - price, fundamentals, dividends - iOCharts

GILD

70.96
-0.65 (-0.91%)
Gilead Sciences, Inc (NASDAQ, USD)
Healthcare >
Drug Manufacturers-General
Market cap
89.00B
Ent value
133.46B
Price/Sales
3.60
Price/Book
4.69
Div yield
4.00%
Div growth
-
Growth years
6
FCF payout
45.88%
Trailing P/E
723.55
Forward P/E
10.67
PEG
516.82
EPS growth
-10.50%
1 year return
9.09%
3 year return
-1.24%
5 year return
-2.07%
10 year return
13.68%
Last updated: 2021-09-20

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open70.93
Daily high71.91
Daily low70.34
Daily Volume9.33M
All-time high122.21
1y analyst estimate74.49
Beta0.40
EPS (TTM)0.10
Dividend per share2.84
Ex-div date14 Sep 2021
Next earnings date27 Oct 2021

Downside potential

Loading...
Downside potential data
GILDS&P500
Current price drop from All-time high-41.94%-4.23%
Highest price drop-70.83%-56.47%
Date of highest drop7 Jun 19949 Mar 2009
Avg drop from high-24.18%-11.47%
Avg time to new high23 days12 days
Max time to new high1573 days1805 days

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.84
Dividend yield4.00%
Payout frequencyQuarterly
Maximum yield5.01%
Average yield3.53%
Minimum yield2.30%
Discount to avg yield11.82%
Upside potential13.40%
Yield as % of max yield79.84%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.00%
Current yield distribution24.92%
Yield at 100% (Min)2.30%
Yield at 90%2.77%
Yield at 80%2.92%
Yield at 50% (Median)3.62%
Yield at 20%4.12%
Yield at 10%4.32%
Yield at 0% (Max)5.01%

Dividend per share

Loading...
Dividend per share data
Years of growth6 years
CCC statusDividend Challenger
Dividend per share2.84
Payout frequencyQuarterly
Ex-div date14 Sep 2021
EPS (TTM)0.10
EPS (1y forward)6.65
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
GILDS&P500
DGR MR4.41%7.68%
DGR TTM5.24%-2.66%
DGR 3 years9.35%5.82%
DGR 5 years-6.23%
DGR 10 years-9.64%
DGR 15 years-6.71%
Time since last change announced232 days
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM2804.07%45.88%
Average--
Forward42.71%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E723.55
Price to OCF10.90
Price to FCF11.84
Price to EBITDA28.26
EV to EBITDA42.38

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.60
Price to Book4.69
EV to Sales5.41

FINANCIALS

Per share

Loading...
Per share data
Current share count1.25B
EPS (TTM)0.10
FCF per share (TTM)6.00

Income statement

Loading...
Income statement data
Revenue (TTM)24.69B
Gross profit (TTM)20.12B
Operating income (TTM)4.13B
Net income (TTM)123.00M
EPS (TTM)0.10
EPS (1y forward)6.65

Margins

Loading...
Margins data
Gross margin (TTM)81.48%
Operating margin (TTM)16.75%
Profit margin (TTM)0.50%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash4.07B
Net receivables3.92B
Total current assets13.28B
Goodwill8.33B
Intangible assets34.78B
Property, plant and equipment4.99B
Total assets67.49B
Accounts payable4.08B
Short/Current long term debt30.17B
Total current liabilities9.71B
Total liabilities48.53B
Shareholder's equity18.96B
Net tangible assets-24.16B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)8.17B
Capital expenditures (TTM)650.00M
Free cash flow (TTM)7.52B
Dividends paid (TTM)3.45B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity0.68%
Return on Assets0.18%
Return on Invested Capital0.25%
Cash Return on Invested Capital15.15%
COMPANY DETAILS
GILD (Gilead Sciences, Inc) company logo
Marketcap
89.00B
Marketcap category
Large-cap
Description
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Employees
13600
Investor relations
SEC filings
CEO
Daniel O'Day
Country
USA
City
Foster City
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 21, 2021
Myelodysplastic syndromes, or MDS, is a rare type of blood cancer primarily affecting people over the age of 65. In fact, it’s such a rare and largely unknown illness that most people living with M...
September 20, 2021
Gilead Sciences (GILD) closed at $70.96 in the latest trading session, marking a -0.91% move from the prior day.
September 20, 2021
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
September 20, 2021
FOSTER CITY, Calif., September 20, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the...
September 17, 2021
Yahoo Finance’s Anjalee Khemlani reports the FDA advisory panels' second vote regarding Covid-19 boosters.
September 17, 2021
Yahoo Finance’s Anjalee Khemlani reports the latest on the FDA’s decision regarding covid booster shots.
September 17, 2021
Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.
September 17, 2021
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Fin...
September 16, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) w...
September 16, 2021
FOSTER CITY, Calif., September 16, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed...
Next page